×

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

  • US 9,211,289 B2
  • Filed: 11/10/2014
  • Issued: 12/15/2015
  • Est. Priority Date: 01/16/2003
  • Status: Expired due to Term
First Claim
Patent Images

1. A method for treating side-effects caused or exacerbated by a dopaminergenic agent-associated therapy comprising administering an therapeutically effective amount of a serotonin 2A or 2C receptor inverse agonist to a patient on a dopaminergenic agent, wherein the serotonin 2A or 2C receptor inverse agonist is a compound of Formula (I) or a salt thereof:

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×